Overview

TD-9855 Mass Balance Study

Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the absorption, distribution, metabolism, and excretion (ADME) of a single oral dose of [14C]TD-9855
Phase:
Phase 1
Details
Lead Sponsor:
Theravance Biopharma
Theravance Biopharma R & D, Inc.